|
|
Volumn 252, Issue 9, 2005, Pages 1011-1020
|
|
Why have neuroprotectants failed? Lessons learned from stroke trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE;
4 PHOSPHONOMETHYLPIPECOLIC ACID;
[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID;
ACETYLSALICYLIC ACID;
ALTEPLASE;
APTIGANEL;
ARUNDIC ACID;
CITICOLINE;
CLOMETHIAZOLE;
CP 101 266;
DESMOTEPLASE;
DIAZEPAM;
DISUFENTON SODIUM;
EBSELEN;
GAVESTINEL;
GLYCERYL TRINITRATE;
INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY;
LUBELUZOLE;
MAGNESIUM;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NALMEFENE;
NEUROPROTECTIVE AGENT;
NEUTROPHIL INHIBITORY FACTOR;
NITRIC OXIDE;
PIRACETAM;
RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;
REPINOTAN;
SODIUM CHANNEL BLOCKING AGENT;
TIRILAZAD;
UK 279 276;
UNCLASSIFIED DRUG;
ALGORITHM;
BLEEDING;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIAL;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG BRAIN LEVEL;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG SAFETY;
DRUG TOLERABILITY;
FOLLOW UP;
HALLUCINATION;
HUMAN;
HYPOTENSION;
NEUROPROTECTION;
PRIORITY JOURNAL;
QT PROLONGATION;
RATING SCALE;
REVIEW;
STATISTICAL ANALYSIS;
THROMBOPHLEBITIS;
TIME;
TREATMENT FAILURE;
TREATMENT OUTCOME;
ANIMAL;
ANIMALS;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIALS;
HUMANS;
NEUROPROTECTIVE AGENTS;
|
|
EID: 25144518193
PISSN: 03405354
EISSN: None
Source Type: Journal
DOI: 10.1007/s00415-005-0933-6 Document Type: Review |
|
Times cited : (21)
|
|
References (0)
|
